Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Decreased by Community Trust & Investment Co.

Community Trust & Investment Co. trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% in the third quarter, Holdings Channel.com reports. The fund owned 32,674 shares of the medical research company’s stock after selling 371 shares during the period. Thermo Fisher Scientific makes up approximately 1.3% of Community Trust & Investment Co.’s investment portfolio, making the stock its 26th largest position. Community Trust & Investment Co.’s holdings in Thermo Fisher Scientific were worth $20,211,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. CFM Wealth Partners LLC bought a new position in Thermo Fisher Scientific during the 1st quarter worth $216,000. Elevated Capital Advisors LLC grew its stake in Thermo Fisher Scientific by 6.2% during the 1st quarter. Elevated Capital Advisors LLC now owns 1,372 shares of the medical research company’s stock worth $797,000 after buying an additional 80 shares during the last quarter. Brookstone Capital Management grew its stake in Thermo Fisher Scientific by 252.4% during the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock worth $2,550,000 after buying an additional 3,142 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 14.6% during the 1st quarter. Revolve Wealth Partners LLC now owns 433 shares of the medical research company’s stock worth $251,000 after buying an additional 55 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC grew its stake in Thermo Fisher Scientific by 359.0% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 5,334 shares of the medical research company’s stock worth $3,100,000 after buying an additional 4,172 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $586.25 on Wednesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. The stock has a market cap of $223.95 billion, a P/E ratio of 36.37, a P/E/G ratio of 3.85 and a beta of 0.77. The firm has a 50 day simple moving average of $607.55 and a 200 day simple moving average of $584.45. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same period last year, the company posted $5.15 earnings per share. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,860,920.55. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,860,920.55. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,084 shares of company stock worth $14,094,292. 0.34% of the stock is owned by company insiders.

Analyst Ratings Changes

TMO has been the subject of a number of analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $767.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, September 20th. Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 price target for the company. Raymond James boosted their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Bernstein Bank boosted their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday. Finally, Wells Fargo & Company started coverage on Thermo Fisher Scientific in a report on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $656.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.